Financial Analysis: Talphera (NASDAQ:TLPH) & Scienture (NASDAQ:SCNX)

Scienture (NASDAQ:SCNX) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Scienture and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Talphera	N/A	-87.28%	-51.36%

Institutional & Insider Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Scienture and Talphera”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	34.14	-$41.51 million	($2.10)	-0.17
Talphera	$30,000.00	2,145.61	-$14.29 million	($0.27)	-4.59

Talphera has lower revenue, but higher earnings than Scienture. Talphera is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Scienture and Talphera, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	1	0	2.00
Talphera	1	1	2	0	2.25

Scienture presently has a consensus price target of $1.50, suggesting a potential upside of 319.58%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 141.94%. Given Scienture’s higher probable upside, equities analysts clearly believe Scienture is more favorable than Talphera.

Risk and Volatility

Scienture has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Summary

Scienture beats Talphera on 7 of the 13 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.